Viatris to Acquire Pacira BioSciences for $1.65B in Cash, Adding Non-Opioid Pain Franchise
VTRS sits 80% above its 52-week low of $9.69.
Summary
Viatris agreed to acquire Pacira BioSciences for $1.65 billion in cash ($36.50/share), adding EXPAREL and ZILRETTA to its portfolio and positioning itself as a leader in non-opioid pain management. The deal is expected to close by end of 2026 and be immediately accretive.
Updates
· SEC SC TO-C — Viatris launched the tender offer for Pacira at $36.50 per share, open for 10 business days, with a $62 million termination fee.
Key Events · M&A and Partnerships · VTRS
-
Acquisition of Pacira BioSciences
Viatris entered into a definitive agreement to acquire all outstanding shares of Pacira BioSciences for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion.
-
Financial Impact
Pacira generated approximately $746 million in revenue and $177 million in adjusted EBITDA for the twelve months ended June 30, 2026. Viatris expects the deal to be immediately accretive to financial guidance metrics and to fund it primarily from excess cash with minimal impact on gross leverage ratio (~2.9x at close).
-
Synergies and Integration
Viatris identified over $50 million of annual cost synergies expected through end of 2028, with one-time costs to achieve synergies of approximately $75 million. The deal adds two marketed, patent-protected products — EXPAREL and ZILRETTA — and expands Viatris' U.S. commercial and R&D capabilities.
-
Timeline and Conditions
The transaction is expected to close by the end of 2026, subject to HSR clearance and tender of a majority of Pacira shares. The deal is structured as a tender offer followed by a second-step merger under Section 251(h) of the DGCL, requiring no Pacira stockholder vote.
Analysis · VTRS · Life Sciences
Viatris is acquiring Pacira BioSciences for $36.50 per share in cash, a $1.65 billion all-cash deal that adds two marketed, patent-protected, high-margin products — EXPAREL and ZILRETTA — to its innovative medicines portfolio. The transaction is expected to close by the end of 2026 and be immediately accretive to Viatris' financial guidance metrics. Pacira generated approximately $746 million in revenue and $177 million in adjusted EBITDA over the last twelve months, and Viatris expects over $50 million in annual cost synergies by the end of 2028. The deal is structured as a tender offer followed by a second-step merger under Section 251(h), requiring no Pacira stockholder vote, with a $62 million termination fee payable by Pacira under certain circumstances. This is a significant strategic move that positions Viatris as a leader in non-opioid pain therapies and leverages its global infrastructure to expand the products internationally.
How filings like this one have moved
In the 30 days to Oct 8, 2026, 42.9% of the 331 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VTRS was trading at $17.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.1B. The 52-week trading range was $9.69 to $18.43. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.